Immutep

We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.

We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.

Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR's).  

Latest Media Releases

Latest News

Interviews / by Rachael Jones - A month ago

Immutep (ASX:IMM) company update

03 Dec 2020 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company, discussing a recent capital raise and results in lung cancer and he…